- Sarepta Therapeutics (NASDAQ:SRPT +0.3%) Q2 results: Revenues: $0; R&D Expense: $44.3M (+51.7%); G&A: $17.8M (+38.0%); Operating Loss: ($62.1M) (-47.5%); Net Loss: ($62.3M) (-48.7%); Loss Per Share: ($1.35) (-33.7%); Non-GAAP Loss Per Share: ($1.19) (-36.8%); Quick Assets: $123.2M (-36.0%).
- No guidance given.
Sarepta Therapeutics net loss widens in Q2
Recommended For You
About SRPT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRPT | - | - |
Sarepta Therapeutics, Inc. |